Monnica Williams, Ph.D.
Clinical Psychologist; Associate Professor, University of Ottawa; OCD and Psychedelic Equity Researcher
A leading voice on racial equity in psychedelic research and therapy, and one of the few researchers conducting clinical trials specifically focused on MDMA-assisted therapy for PTSD in communities of color.
Biography
Monnica Williams is a clinical psychologist and associate professor at the University of Ottawa whose research and advocacy have made her the most prominent voice addressing racial equity in psychedelic medicine. She specializes in anxiety disorders, OCD, and trauma in communities of color, and has become increasingly focused on ensuring that the psychedelic therapy renaissance does not repeat the racial exclusions of the earlier psychedelic research era.
Williams's critique of racial disparities in psychedelic research begins with data: the clinical trials that have produced the most-cited evidence for psilocybin and MDMA therapy have enrolled populations that are overwhelmingly white, highly educated, and economically privileged — not representative of the communities with the highest rates of trauma, PTSD, and treatment-resistant mental illness. She has argued that this creates an evidence gap and a justice gap simultaneously: the treatments being developed may not generalize to populations with different cultural contexts and life experiences, and the benefits will likely flow first to those already privileged in medical access.
She has been involved in designing and conducting MDMA-assisted therapy studies with diverse participants, including Black Americans with PTSD — addressing both representation in the evidence base and the cultural competency needed to deliver this therapy effectively across racial backgrounds. Her work addresses the particular challenges of trauma-focused psychedelic therapy with participants who may have histories of medical mistreatment and culturally specific trauma responses.
Williams has published widely on cultural considerations in psychedelic therapy, spoken at major psychedelic conferences, and contributed to policy discussions about access and equity as regulatory approval approaches.
Organizations
Why They Matter to the LearnShrooms Community
If psychedelic-assisted therapy achieves regulatory approval based primarily on trials with white participants, the evidence base will be incomplete and the structural mechanisms directing access to primarily affluent white patients will already be entrenched. Williams's research and advocacy address this problem while it is still possible to correct — ensuring that the evidence base and the access infrastructure are built equitably from the start.
Legal Context
For the legal landscape where Monnica Williams, Ph.D. operates, see psilocybin laws in International.